Cytovation Raises $20 Million In Series A Financing Round To Advance Clinical Development Of Cypep-1, A First-In-Class Targeted Tumor Membrane Immunotherapy
Cytovation Raises $20 Million In Series A Financing Round To Advance Clinical Development Of Cypep-1, A First-In-Class Targeted Tumor Membrane Immunotherapy
01/25/22, 2:00 AM
Location
bergenMoney raised
$20 million
Round Type
series a
Cytovation AS, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy, announces the successful closing of its Series A financing round, raising a total of NOK 180 million ($20 million).
Company Info
Location
bergen, vestland, norway
Additional Info
Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell membrane of tumor cells. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit www.cytovation.com.